Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a notable increase on March 16, 2026, contrasting with a slight decline in the China Shanghai Composite. Despite recent gains, the company has faced challenges over the past year, underperforming the broader market, while maintaining a large-cap status in the pharmaceuticals sector.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a decline in stock performance today, contrasting with the minor decrease in the China Shanghai Composite. Despite recent gains over the past week, the company has struggled year-to-date and over the past year, facing challenges such as low returns and negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a notable increase in stock performance on March 10, 2026, reaching an intraday high. The company reported positive results over the last four quarters, with net sales of CNY 217.79 million and improved operational efficiency, despite facing longer-term challenges.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant rise in its stock today, contrasting with the modest gain of the China Shanghai Composite. However, the company has struggled over the past year, with negative returns and financial challenges, despite reporting positive quarterly results and a substantial market capitalization.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. The company has struggled over the past year, with a notable year-to-date drop and low return on capital employed, despite reporting positive results in recent quarters.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. faced a notable stock decline today, contrasting with the broader market. While the company has shown a strong annual return, it struggles with management efficiency and consistent losses, raising concerns about its sustainability. Nonetheless, it reported positive results for the last four quarters.